RxDoctor Payments DataLook up a doctor →

Nakhle Saba, MD

Hematology & Oncology · Baton Rouge, LANPI 1275714669

Payments from drug & device makers

$2,444,358in general payments, 2019–2025

Across 1,319 payments — averaging $1853.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$376K
  • Incyte Corporation$361K
  • Pharmacyclics LLC, An Abbvie Company$234K
  • Eli Lilly$223K
  • AbbVie$172K
  • Genentech, Inc.$153K
  • plus $925K from 54 others
$1,273in research payments, 2019–2025

Across 3 payments — averaging $424.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$1K
  • AbbVie$40

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck17$375,589
Incyte Corporation183$361,039
Pharmacyclics LLC, An Abbvie Company316$234,129
Eli Lilly13$223,340
AbbVie214$172,484
Genentech, Inc.5$152,553
Acerta Pharma LLC19$128,002
Johnson & Johnson108$107,470
Beigene USA, Inc.54$96,959
Beone Medicines USA, Inc.40$88,069
Astrazeneca UK Limited11$83,750
Kyowa Kirin, Inc.29$79,627
Lilly USA, LLC49$73,057
ADC Therapeutics America, Inc.38$39,198
Beigene, Ltd.3$35,249
Morphosys AG8$34,895
E.r. Squibb & Sons, L.L.C.10$31,191
Jazz Pharmaceuticals Inc.10$29,689
Seagen Inc.14$29,067
Karyopharm Therapeutics Inc.9$20,799
Pfizer8$18,855
Gilead11$5,905
Genentech USA, Inc.20$5,340
Janssen Scientific Affairs, LLC5$4,289
Amgen7$3,984
AstraZeneca(2 entities)11$3,078
Ipsen Biopharmaceuticals, Inc1$2,175
Epizyme, Inc.1$1,750
Novartis15$449
Takeda Pharmaceuticals U.S.A., Inc.13$358
Daiichi Sankyo Inc.10$258
Bristol Myers Squibb12$247
Sobi, Inc4$195
Genmab U.S., Inc.3$177
Astellas Pharma US Inc7$155
Dendreon Pharmaceuticals LLC3$140
Medtronic1$127
Rigel Pharmaceuticals, Inc.3$74
Sanofi-aventis U.S. LLC3$74
Servier Pharmaceuticals LLC3$62
Adaptive Biotechnologies Corporation2$43
GSK2$35
Acrotech Biopharma Inc.2$34
Exelixis Inc.2$32
Recordati_rare_diseases_inc.2$31
AVEO Pharmaceuticals, Inc.2$30
Syndax Pharmaceuticals, Inc.1$29
Legend Biotech USA Inc.1$28
Apellis Pharmaceuticals, Inc.1$26
Sanofi1$24
Azurity Pharmaceuticals, Inc.1$24
Biolinerx USA, Inc.1$20
Agios Pharmaceuticals, Inc.1$20
EUSA Pharma (US) LLC1$19
EMD Serono, Inc.1$17
Eisai Inc.1$16
Bayer1$16
Aurobindo Pharma USA, Inc.1$16
Teva Pharmaceuticals USA, Inc.1$15
Spectrum Pharmaceuticals Inc.1$12

How this compares

$2,444,358 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.

See all hematology & oncology providers in Louisiana

Medicare billing

Part B allowed, 2024
$25,438
Medicare patients
52
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →